Educational Notice: Peptidings provides information for educational and research purposes only. Peptides discussed on this site are typically studied in laboratory environments and may not be approved for medical use in humans. The information presented here does not constitute medical advice.
TB-500 is among the most widely discussed peptides in tissue-repair research, yet it is also one of the most commonly misunderstood. Much of the confusion begins with its name: TB-500 is not identical to the full-length protein thymosin beta-4, though the two terms are frequently used interchangeably in non-technical sources. This article explains what TB-500 actually is, how it differs from its parent molecule, what the research literature says about its biological activity, and where critical gaps in the evidence remain.
Whether you are a researcher evaluating TB-500 for laboratory study, a clinician following peptide science as it moves toward clinical application, or someone who wants to understand the compound beyond forum posts and marketing claims, this guide aims to give you a thorough, evidence-based foundation. We will cover the peptide’s biochemical properties, its proposed mechanisms of action, the key studies that have shaped scientific interest, and the safety and regulatory considerations that any responsible discussion must include.
The article is organized to move from foundational knowledge—what TB-500 is and where it came from—into the deeper science of how it appears to work in experimental settings. From there, we examine the specific research areas where the most evidence has accumulated, evaluate common marketing claims against the actual data, and address the important questions around cancer risk, anti-doping status, and regulatory classification that distinguish TB-500 from many other research peptides.
For the peptide most frequently discussed alongside TB-500, see our comprehensive article on BPC-157. For other related compounds, see the Related Peptides and Selected References sections at the end of this article.
Table of Contents
BLUF: Bottom Line Up Front
Thin Ice— Used widely in racehorses, never tested in people
TB-500 is a synthetic fragment of thymosin beta-4, a healing protein. It’s popular in elite sports medicine and equine sports—trainers inject it into racehorses for injury recovery and athletic performance. Banned by WADA in sports. Zero human trials exist. The entire track record is in horses, not people. You’re effectively testing an unapproved compound on yourself because vets use it on million-dollar thoroughbreds.
| Field | Detail |
|---|---|
| Peptide Name | TB-500 (synthetic fragment of Thymosin Beta-4) |
| Type | Synthetic heptapeptide |
| Amino Acid Length | 7 amino acids (Ac-LKKTETQ) |
| Parent Molecule | Thymosin Beta-4 (Tβ4), a 43-amino-acid endogenous peptide |
| Origin | Corresponds to amino acids 17–23 of thymosin beta-4, first isolated from bovine thymus in 1981 |
| Primary Research Areas | Cell migration, tissue repair, cardiac regeneration, corneal wound healing, neuroprotection |
| First Identified | Thymosin beta-4 isolated by Goldstein and colleagues, 1981; TB-500 developed as synthetic active fragment |
| Molecular Weight | ~889 g/mol (TB-500); ~4,963 g/mol (full-length Tβ4) |
| WADA Status | Prohibited at all times under S2 (Growth Factors and Growth Factor Modulators) |
| Regulatory Status | Investigational compound; not approved by the FDA for human medical use |
TB-500 is a synthetic heptapeptide—a chain of seven amino acids with the sequence Ac-LKKTETQ—that corresponds to the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in nearly every mammalian cell type except red blood cells. The “Ac” prefix indicates that the N-terminal leucine residue is acetylated, a modification that helps protect the peptide from rapid enzymatic degradation.
Thymosin beta-4 was first purified from bovine thymus tissue by Allan Goldstein and colleagues in 1981, and its complete amino acid sequence was subsequently characterized. The protein was initially thought to be a thymic hormone involved in immune cell maturation, but further research revealed that its primary biological function is far broader: Tβ4 is the major G-actin-sequestering molecule in eukaryotic cells. This means it binds to monomeric actin (G-actin) and prevents premature polymerization into filaments, thereby regulating the cytoskeletal dynamics that control cell shape, movement, and division.
TB-500 represents only a small fragment of the full Tβ4 protein—specifically, the region that contains the actin-binding motif. Because it is shorter and simpler to synthesize than the full 43-amino-acid sequence, TB-500 became the form most commonly produced by research chemical suppliers and most widely discussed in biohacking and self-experimentation communities. However, this difference in size is not trivial: the full-length Tβ4 contains additional functional domains that may contribute to biological activity not captured by the TB-500 fragment alone.
This distinction matters more than most sources acknowledge. The vast majority of published scientific research—including the clinical trials, cardiac studies, corneal healing experiments, and neuroprotection work discussed later in this article—was conducted using full-length thymosin beta-4, not the seven-amino-acid TB-500 fragment. When we describe “what the research says,” we are, in most cases, describing research on the parent molecule.
The TB-500 fragment contains the actin-binding motif and shares some biological activity with full-length Tβ4, but it lacks other functional regions that may contribute to the parent molecule’s broader effects. Interpreting Tβ4 research as direct evidence for TB-500 requires caution, because a fragment may not reproduce the full range of domain-dependent interactions observed with the complete protein. This is an important nuance that is frequently glossed over in popular discussions of the peptide.
Throughout this article, we will be explicit about which molecule was used in each study discussed. Where the research was conducted on full-length Tβ4, we say so. Where findings can be reasonably attributed to the actin-binding region shared by both molecules, we note that as well. This level of precision is essential for any honest evaluation of the evidence.
The thymosin story begins in the 1960s and 1970s, when Allan Goldstein and Abraham White at the Albert Einstein College of Medicine isolated a group of small proteins from calf thymus tissue. These proteins, collectively called “thymosin fraction 5,” appeared to influence immune cell maturation. Over the next decade, Goldstein’s laboratory isolated individual components from the fraction and characterized their amino acid sequences.
In 1981, Low, Hu, and Goldstein published the complete amino acid sequence of bovine thymosin beta-4—the 43-amino-acid peptide that would eventually become the parent molecule of TB-500. This foundational work appeared in the Proceedings of the National Academy of Sciences and established the molecular identity that all subsequent research would build upon.
The peptide’s biological significance expanded dramatically when researchers discovered that Tβ4 was not primarily a thymic hormone at all. Instead, it turned out to be the most abundant actin-sequestering peptide in mammalian cells—present at concentrations of up to 0.4 mM in some cell types and playing a fundamental role in cytoskeletal regulation. This reframing shifted the research focus from immunology to cell biology, tissue repair, and regenerative medicine.
The synthetic fragment TB-500 emerged later, initially in veterinary contexts. It gained particular notoriety in the early 2010s when its use in competitive horse racing—administered to accelerate injury recovery in racehorses—became the subject of doping investigations, particularly in Australia. This equine connection is significant because it drove the development of detection methods by anti-doping laboratories and ultimately contributed to the World Anti-Doping Agency adding thymosin beta-4 and its derivatives (including TB-500) to the prohibited substances list in 2018.
The peptide’s transition from veterinary use to human self-experimentation followed a pattern familiar in the peptide research space: published animal and cell-culture studies attracted attention from biohacking communities, who began sourcing TB-500 from research chemical suppliers. This occurred in parallel with increasing clinical interest in the full-length Tβ4 molecule, which was being developed as a pharmaceutical candidate by RegeneRx Biopharmaceuticals for cardiac, ophthalmic, and dermal applications.
The biological activity of thymosin beta-4—and by extension, the TB-500 fragment—centers on several interconnected pathways. Unlike BPC-157, whose proposed mechanism involves VEGF-mediated angiogenesis and fibroblast activation, TB-500’s primary mode of action operates through the cytoskeleton: the internal structural framework that controls how cells move, divide, and organize themselves.
Actin Sequestration and Cytoskeletal Regulation
The most well-characterized function of Tβ4 is its role as a G-actin-sequestering molecule. Actin exists in two forms inside cells: monomeric G-actin (globular) and polymerized F-actin (filamentous). The dynamic balance between these two forms controls cell shape, motility, and mechanical properties. Tβ4 binds G-actin monomers and maintains a reservoir of unpolymerized actin that can be rapidly mobilized when cells need to move, change shape, or divide. By regulating this actin pool, Tβ4 influences processes ranging from wound healing to immune cell migration.
This mechanism is directly relevant to tissue repair because injured tissue requires rapid cell migration into the wound site. When tissue damage occurs, cells at the wound margin must reorganize their cytoskeletons, extend protrusions in the direction of movement, and physically migrate into the damaged area. The availability of G-actin monomers for rapid filament assembly is a rate-limiting factor in this process—and Tβ4’s ability to regulate that availability is central to its proposed therapeutic relevance.
Plain English
Thymosin Beta-4’s primary job is managing actin—the scaffolding protein inside every cell. By controlling how actin assembles and disassembles, it helps cells move to injury sites, which is the first step in tissue repair. TB-500 is a synthetic fragment designed to capture this specific function.
Cell Migration and Tissue Repair
Beyond its actin-sequestering role, Tβ4 has been shown to directly promote cell migration in multiple experimental systems. Studies have demonstrated increased migration rates in endothelial cells, keratinocytes, and cardiac cells exposed to Tβ4. The peptide appears to accelerate the rate at which cells move into wounded areas, which is a distinct and complementary process to the blood vessel formation promoted by peptides like BPC-157.
The cell-migration effect is particularly relevant to cardiac research, where Tβ4 has been shown to promote the migration of epicardial progenitor cells—cells that can potentially contribute to heart tissue repair after injury. Bock-Marquette and colleagues demonstrated in a landmark 2004 Nature publication that Tβ4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt/PKB. This signaling cascade both promotes cell survival (anti-apoptosis) and enhances cell migration—a dual effect that has significant implications for tissue repair.
Angiogenesis and Blood Vessel Formation
Like BPC-157, Tβ4 has been associated with angiogenic activity—the formation of new blood vessels. However, the proposed pathways differ. While BPC-157 is thought to interact primarily through VEGF-related signaling, Tβ4’s angiogenic effects appear to involve endothelial progenitor cell mobilization and Notch signaling pathways. Research has shown that Tβ4 can increase neovascularization in ischemic tissue, which is particularly relevant to the cardiac repair studies discussed below.
Plain English
TB-500 promotes new blood vessel formation through a different pathway than BPC-157. While BPC-157 works mainly through VEGF, TB-500 appears to work by mobilizing endothelial cells to build new capillaries at injury sites.
The angiogenic properties of Tβ4 have also raised one of the most significant safety concerns associated with the peptide: the theoretical potential to promote tumor vascularization. This concern is addressed in detail in the Safety, Risks, and Limitations section.
Anti-Inflammatory Signaling
Tβ4 has demonstrated anti-inflammatory properties in multiple experimental models. The peptide appears to downregulate the expression of inflammatory chemokines and cytokines, and it has been shown to modulate the activity of NF-κB, a master regulator of inflammatory gene expression. In corneal injury models, Tβ4 reduced pro-inflammatory cytokine levels at the wound site while simultaneously promoting tissue repair—suggesting that the peptide may create a more favorable microenvironment for healing by dampening excessive inflammation without suppressing the repair response itself.
Plain English
TB-500 dials down inflammatory signals in animal models, which could explain why it’s associated with faster tissue repair—less inflammation means less collateral damage at the injury site.
This anti-inflammatory activity, combined with the cell migration and anti-apoptotic effects described above, gives Tβ4 what researchers have described as a “multi-functional regenerative” profile—a peptide that simultaneously addresses several different bottlenecks in the tissue repair process.
The research literature on thymosin beta-4 is substantially broader than that on BPC-157, and critically, it includes multiple human clinical trials. The following subsections summarize the primary areas where scientific investigation has been concentrated. Note that most of this research was conducted using full-length Tβ4 unless otherwise specified.
Cardiac Repair and Cardioprotection
The cardiac research on thymosin beta-4 represents the most clinically advanced body of evidence for the peptide. In a landmark 2004 study published in Nature, Bock-Marquette, Saxena, White, DiMaio, and Srivastava demonstrated that Tβ4 activated the survival kinase Akt in cardiomyocytes, reduced cell death after coronary artery ligation in mice, and improved cardiac function. This was the first evidence that a small secreted peptide could simultaneously promote cardiac cell survival and stimulate vessel growth in the injured heart.
Subsequent studies expanded these findings. Bao and colleagues (2013) demonstrated cardioprotection through systemic dosing of Tβ4 following ischemic myocardial injury in rats. Ziegler and colleagues (2018) showed that Tβ4 increased neovascularization and cardiac function in a pig model of chronic myocardial ischemia—a significant step because porcine hearts are anatomically closer to human hearts than rodent models. More recently, Maar, Thatcher, Karpov, Rendeki, Gallyas, and Bock-Marquette (2025) published findings on Tβ4’s modulation of cardiac remodeling through ROCK1 expression regulation in adult mammals.
On the clinical side, a pilot study by Zhu and colleagues (2016) in China examined autologous thymosin beta-4-pretreated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction. This was described as the first human study using Tβ4 in post-heart-attack patients. Additionally, Wang and colleagues (2021) published a Phase I randomized, double-blind study of recombinant human Tβ4 in healthy Chinese volunteers, evaluating safety, tolerability, and pharmacokinetics across multiple dose levels. No dose-limiting toxicities or serious adverse events were observed, and the drug was concluded to be well tolerated and safe.
RegeneRx Biopharmaceuticals has designated RGN-352, its injectable Tβ4-based drug candidate, as a Phase 2-ready candidate for cardiac applications. The FDA also granted orphan drug designation for certain Tβ4-based applications, reflecting recognition of the clinical potential despite the compound’s ongoing investigational status.
Corneal Wound Healing and Ophthalmology
The ophthalmic research on Tβ4 is the furthest advanced in terms of regulatory progress and represents some of the most rigorous clinical evidence available for any application of the peptide. RGN-259, a 0.1% Tβ4 ophthalmic solution developed by RegeneRx and its joint venture ReGenTree, has completed multiple clinical trials.
A Phase II randomized, double-masked, placebo-controlled trial in 72 subjects with moderate to severe dry eye demonstrated significant improvements in corneal staining and ocular discomfort with Tβ4 treatment. Central and superior corneal staining improved significantly compared to placebo, and no adverse events were reported. Multiple Phase III clinical trials have followed, including the SEER-1 trial for neurotrophic keratopathy, in which 60% of RGN-259-treated patients achieved complete corneal healing. The SEER-2 and SEER-3 Phase III trials are also underway. The FDA granted RGN-259 Orphan Drug status for neurotrophic keratopathy treatment in 2013.
In preclinical comparisons, RGN-259 performed equal to or better than existing prescription dry eye treatments (cyclosporine A, diquafosol, and lifitegrast) across multiple efficacy measures in a murine dry eye model. The ophthalmic program is significant for the broader Tβ4 story because it represents the most conventional drug-development pathway the peptide has entered—with proper randomized controlled trials, FDA engagement, and regulatory milestones.
Dermal Wound Healing
Tβ4 has demonstrated wound-healing activity in multiple preclinical models. A foundational study by Malinda, Sidhu, Banaudha, Zhu, Srivastava, and Kleinman (1999) published in the Journal of Investigative Dermatology showed that Tβ4 administration increased reepithelialization by 42% at 4 days and by as much as 61% at 7 days compared to controls in a rat wound model. Tβ4 was also shown to decrease the number of myofibroblasts in wounds, which is associated with reduced scar formation and fibrosis.
A European prospective, randomized clinical study evaluated the safety and tolerability of Tβ4 in venous stasis ulcer patients, providing additional human data on dermal wound healing applications. RegeneRx has designated RGN-137, a topical Tβ4-based formulation, for development in dermal wound healing.
Neurological Injury and Neuroprotection
A substantial body of preclinical research has explored Tβ4’s neuroprotective and neurorestorative properties. Xiong, Mahmood, and Chopp at the Henry Ford Hospital published a series of studies examining Tβ4 treatment in rat models of traumatic brain injury. Their findings, supported by NIH grants, demonstrated that Tβ4 treatment initiated even 6 hours post-injury significantly reduced cortical lesion volume, decreased hippocampal cell loss, and improved functional recovery on both sensorimotor and spatial learning tests.
The proposed neuroprotective mechanisms include promotion of angiogenesis, neurogenesis, and oligodendrogenesis in injured brain tissue. Tβ4 appears to amplify endogenous neurorestorative processes rather than simply preventing initial damage—a distinction that is significant because it expands the potential therapeutic window beyond the first minutes after injury.
Additional neurological research has examined Tβ4 in models of embolic stroke, multiple sclerosis, and spinal cord injury. More recently, Stewart, Hejl, Guleria, and Gupta (2025) published research in Scientific Reports on Tβ4’s role in stabilizing hypoxia-induced blood-brain barrier disruption through S1PR1-dependent mechanisms. This remains one of the more active areas of preclinical investigation, though no human clinical trials specifically targeting neurological injury have been completed.
Musculoskeletal Tissue
While BPC-157 has the stronger research profile in tendon and ligament repair specifically, Tβ4 has been studied in broader musculoskeletal contexts. Spurney and colleagues (2010) evaluated chronic administration of Tβ4 in the dystrophin-deficient mouse model (a model of Duchenne muscular dystrophy) and observed improvements in skeletal and cardiac muscle function. The peptide’s cell-migration properties are theoretically relevant to musculoskeletal repair because damaged muscle and connective tissue require cell infiltration for regeneration. However, the musculoskeletal research on Tβ4 is less extensive than the cardiac, ophthalmic, or neurological literature, and this is an area where TB-500’s reputation may exceed its evidence base.
| Claim | Current Evidence |
|---|---|
| “Heals injuries faster” | Animal research demonstrates accelerated healing across multiple tissue types (skin, cornea, cardiac). The cell-migration mechanism is well characterized. Phase II and III human trials exist for corneal healing; cardiac pilot data exists. Musculoskeletal claims are less well supported. |
| “Repairs the heart” | This is one of the strongest research areas. Preclinical cardiac studies are extensive, a Phase I safety trial in healthy volunteers showed tolerability, and a pilot study in post-MI patients has been published. RGN-352 is Phase 2-ready. Evidence is promising but large-scale efficacy trials are still needed. |
| “Fixes tendons and muscles” | Evidence is mixed. Tβ4 promotes cell migration into damaged tissue, which is relevant to musculoskeletal repair, but direct tendon/ligament studies are more limited than for BPC-157. Some animal data exists for muscle dystrophy models. This claim is often overstated. |
| “Neuroprotective” | Preclinical evidence from multiple research groups (notably Xiong, Mahmood, and Chopp) is substantial for traumatic brain injury models. However, no human neurological trials have been completed. The research is promising but remains preclinical. |
| “Anti-inflammatory” | Demonstrated in multiple preclinical models, including corneal injury and dry eye. The anti-inflammatory mechanism (NF-κB modulation, cytokine downregulation) is reasonably well characterized. Human evidence comes primarily from ophthalmic trials. |
| “Safe with no side effects” | Phase I human data shows tolerability at tested doses for full-length Tβ4. However, the cancer risk concern (Tβ4 overexpression in multiple tumor types) has not been resolved. Long-term safety is unknown. This claim should be approached with caution. |
Unlike BPC-157, where the absence of human clinical trials is the central limitation, thymosin beta-4 has entered human studies through several pathways. This gives Tβ4 a materially different evidence profile—though important caveats remain.
Phase I safety data. Wang and colleagues (2021) published a randomized, double-blind, Phase I study of recombinant human Tβ4 in 54 healthy Chinese volunteers. Seven dose cohorts received single intravenous doses ranging from 0.05 to 25.0 μg/kg. An additional 30 subjects received multiple daily doses across three cohorts. No dose-limiting toxicities or serious adverse events were observed. Plasma concentrations increased proportionally with dose, and no accumulation was detected after continuous administration.
Cardiac pilot study. Zhu and colleagues (2016) conducted the first human study using Tβ4 in patients following acute myocardial infarction. While this was a small pilot study, it provided initial human data on cardiac applications and was described as demonstrating potential clinical benefits for tissue repair and cardiac function improvement.
Ophthalmic clinical program. The most advanced human evidence comes from the RGN-259 ophthalmic program. Phase II and Phase III trials have been conducted in dry eye and neurotrophic keratopathy, with significant improvements in corneal healing observed. Three Phase III trials (SEER-1, SEER-2, SEER-3) have been conducted or are underway for neurotrophic keratopathy.
Dermal wound trial. A European prospective, randomized study evaluated Tβ4 safety and tolerability in venous stasis ulcer patients, providing additional human safety data.
It is essential to note, however, that virtually all of this human clinical work was conducted using full-length thymosin beta-4—not the TB-500 fragment that is available through research chemical suppliers. No published human clinical trials have been conducted specifically on TB-500. This distinction is critical: the human safety and efficacy data applies to the full 43-amino-acid Tβ4 molecule and cannot be automatically extended to the 7-amino-acid fragment without additional research.
TB-500 and thymosin beta-4 present a more complex safety picture than many other research peptides. Several important considerations should be weighed by anyone evaluating these compounds.
The Cancer Question
This is the most significant safety concern unique to TB-500/Tβ4, and it warrants direct discussion rather than the passing mention it typically receives. Multiple studies have found that thymosin beta-4 is overexpressed in various tumor types, including colorectal, pancreatic, breast, ovarian, lung, and renal cancers. Research has shown that elevated Tβ4 expression correlates with increased metastatic potential, tumor invasiveness, and in some cases, poorer patient prognosis.
The biological logic is straightforward: the same properties that make Tβ4 therapeutically interesting—promotion of cell migration, angiogenesis, and anti-apoptotic signaling—are also properties that cancer cells exploit to grow, spread, and resist treatment. A compound that helps healthy cells migrate into wounded tissue could, in theory, also help cancer cells migrate to distant sites (metastasis). A compound that promotes new blood vessel formation could also vascularize tumors.
However, the picture is not entirely one-directional. A study in multiple myeloma found that decreased Tβ4 expression was associated with poorer prognosis, and Tβ4 overexpression in myeloma cells actually led to decreased proliferative and migratory capacities and increased sensitivity to apoptosis. Additionally, a 2023 study found that exogenous Tβ4 suppressed lung cancer in an IPF-lung cancer mouse model, possibly through inhibition of JAK2/STAT3 signaling. These findings suggest the relationship between Tβ4 and cancer is context-dependent and more nuanced than a simple “promotes cancer” narrative.
| Tumor Type | Direction | Key Finding | Proposed Mechanism | Citation |
|---|---|---|---|---|
| Colorectal cancer | Pro-tumor | Tβ4 overexpression increased invasion in SW480 cells and correlated with distant metastasis in human colorectal carcinoma. Cells overexpressing Tβ4 were also more resistant to apoptosis induced by T cells and chemotherapeutic agents. | ILK activation, epithelial-mesenchymal transition, apoptosis resistance | Wang et al. (2003, 2004) Oncogene; Huang et al. (2006) Oncogene |
| Pancreatic cancer | Pro-tumor | Tβ4 mRNA was elevated in pancreatic cancer cell lines compared to normal ductal epithelium; exogenous Tβ4 increased pro-inflammatory cytokine secretion (IL-6, IL-8, MCP-1). JNK signaling pathway activated. | JNK pathway activation, pro-inflammatory cytokine signaling | Zhang et al. (2008) Cancer Biology & Therapy |
| Non-small cell lung cancer | Pro-tumor | Tβ4 expression was higher in NSCLC tissue than normal tissue and associated with TNM stage, differentiation, and metastasis. MALAT-1 and Tβ4 together predicted metastasis and survival in early-stage NSCLC. | Cell proliferation, migration, Notch signaling | Ji et al. (2003) Oncogene; Huang et al. (2016) Acta Biochim. Biophys. Sin. |
| Head and neck squamous cell | Pro-tumor | TMSB4X overexpression correlated with advanced stage disease; knockdown reduced proliferation, invasion, and lymph node metastasis. Poor overall survival (p = 0.006) and recurrence-free survival (p = 0.013). | Actin cytoskeleton reorganization, cell migration | Tsai et al. (2017) Scientific Reports |
| Gastric GIST | Pro-tumor | Tβ4 immunoexpression directly correlated with higher risk groups, larger tumor size, mitotic count, and necrosis. Inversely correlated with overall survival (p = 0.042). | Cell motility, angiogenesis | Tβ4 in gastric GISTs (2017) ScienceDirect |
| Fibrosarcoma (mouse) | Pro-tumor | Tβ4 upregulation converted weakly tumorigenic cells to develop tumors and form lung metastases; antisense knockdown reduced both. | Actin-based cytoskeletal organization regulating tumorigenicity | Kobayashi et al. (2002) Am. J. Pathol. |
| Multiple myeloma | Anti-tumor | Tβ4 expression was significantly lower in myeloma cells vs. normal plasma cells; overexpression decreased proliferation and migration and increased apoptosis sensitivity. Mice with Tβ4-overexpressing myeloma cells survived longer (88.9 vs. 65.9 days, p < 0.05). | Inhibition of proliferative and migratory capacity in hematologic malignancy | Choi et al. (2010) Haematologica |
| IPF-associated lung cancer | Anti-tumor | Exogenous recombinant Tβ4 inhibited lung cancer cell proliferation and delayed progression in an IPF-lung cancer mouse model. Proposed mechanism: inhibition of IL-6/JAK2/STAT3 signal transduction. | JAK2/STAT3 pathway suppression, anti-inflammatory | MDPI (2023) Int. J. Mol. Sci. |
| Breast, ovarian, uterine | Correlational | Increased Tβ4 expression reported across these tumor types in published surveys. Specific mechanistic studies are less developed than for colorectal or lung cancer. | Likely related to cell motility and angiogenic properties | Reviewed in Sribenja & Bhatt (2010) Future Oncol. |
| Renal cell carcinoma | Correlational | Tβ4 gene upregulation documented in renal cell carcinoma compared to normal kidney tissue. | Cell motility, potential prognostic marker | Reviewed in Cha et al. (2003) J. Natl. Cancer Inst. |
The honest assessment is that the cancer risk has not been resolved by current research. Short-term systemic administration (as in the cardiac pilot study) presents a different risk profile than chronic use. But long-term systemic administration of a compound that promotes angiogenesis, cell migration, and anti-apoptotic signaling should be approached with caution, particularly by individuals with any history of malignancy.
Limited Fragment-Specific Research
As emphasized throughout this article, the human clinical data exists for full-length Tβ4, not for the TB-500 fragment. The safety profile of full-length Tβ4 cannot be automatically assumed to apply to TB-500. Additionally, the TB-500 fragment lacks the additional functional domains present in the parent molecule, which means both the efficacy and the safety profile may differ in ways that have not been characterized.
Long-Term Effects Unknown
No long-term safety data exists for either TB-500 or full-length Tβ4 in humans. The Phase I trial evaluated tolerability over a 28-day observation period. Chronic or repeated use over months or years—which is the pattern in self-experimentation communities—has not been studied in any controlled setting.
Quality and Purity Concerns
TB-500 is primarily sourced through research chemical suppliers rather than pharmaceutical manufacturers. WADA-funded research has characterized the metabolic profile of TB-500, and anti-doping laboratories have developed detection methods for the peptide and its metabolites. This is relevant because it confirms that the TB-500 products in circulation do contain the expected peptide sequence—but it does not address purity, contaminants, or degradation in individual products from individual suppliers. Independent laboratory verification remains essential for any research application.
Anti-Doping Status
TB-500 is explicitly prohibited by the World Anti-Doping Agency under Section S2 of the Prohibited List, classified as a growth factor and growth factor modulator. The prohibition applies at all times—both in-competition and out-of-competition. Thymosin beta-4 and all derivatives, including TB-500, were specifically added to the prohibited list in 2018, partly driven by the peptide’s history of use in equine racing doping. The U.S. Department of Defense has also adopted WADA’s prohibited list categories for military personnel. Any competitive athlete or military service member subject to drug testing must avoid TB-500 entirely.
Legal and Regulatory Status
TB-500 is not approved by the U.S. Food and Drug Administration for any human use. Unlike BPC-157, which was widely available through compounding pharmacies before FDA Category 2 restrictions, TB-500 has primarily been distributed through research chemical vendors, typically labeled “for research purposes only.” This positioning has somewhat insulated TB-500 from the specific FDA actions that affected BPC-157’s availability through compounding, but it also means there is even less pharmaceutical-grade supply and regulatory oversight for the compound.
Regulatory status varies by jurisdiction internationally. Full-length thymosin beta-4 is being developed as a pharmaceutical candidate through the RegeneRx pipeline, which involves standard FDA regulatory engagement. However, the synthetic TB-500 fragment available through research suppliers exists entirely outside this regulated pathway.
In experimental research settings, the following practices have been reported in the published literature on TB-500 and Tβ4.
Administration Routes
In published research, Tβ4 has been administered via intraperitoneal injection (in animal studies), intravenous injection (in the Phase I human trial and cardiac research), and topical application (in the ophthalmic clinical program). TB-500 in self-experimentation contexts is typically administered via subcutaneous or intramuscular injection, though no standardized protocols exist for human use. Dosing in animal studies has ranged from micrograms to milligrams per kilogram of body weight. The Phase I human trial used doses ranging from 0.05 to 25.0 μg/kg intravenously.
Peptide Preparation and Storage
In laboratory environments, TB-500 is typically supplied in lyophilized (freeze-dried) form. Lyophilization removes moisture from the compound, allowing it to remain stable during storage and transport. Before use in experimental studies, lyophilized peptides are commonly dissolved in sterile laboratory solvents such as sterile water or bacteriostatic solutions, restoring the peptide to a liquid form suitable for research applications. Maintaining sterile technique is essential when handling peptides in laboratory environments.
Storage Conditions
Peptides used in research are typically stored under temperature-controlled conditions to preserve molecular stability. In many laboratory settings, refrigeration is used for short-term storage, while freezing may be employed for long-term preservation. Light exposure and repeated freeze-thaw cycles are generally avoided, as these practices help maintain the structural integrity of peptide compounds during experimental work. WADA-funded metabolism research has shown that TB-500 undergoes serial cleavage at the C-terminus, while the N-terminal acetylation provides protection from degradation—a characteristic that is relevant to both storage stability and in vivo half-life.
TB-500 and its parent molecule thymosin beta-4 have been studied across a range of dosing protocols in published, peer-reviewed research. Unlike the self-experimentation protocols discussed in the following section, these doses were administered under controlled experimental conditions—with defined endpoints, systematic monitoring, and institutional oversight. They represent the only dosing information that carries scientific weight, and they form the necessary baseline against which all other dosing discussions should be evaluated.
The table below summarizes the dosing protocols reported across the published literature, organized by study category: human clinical studies, cardiac and neurological animal studies, and wound healing and other preclinical models. Several patterns are worth noting before examining the data. First, the most commonly used dose across the animal literature is approximately 6 mg/kg, a level that multiple independent research groups converged on as providing therapeutic benefit without adverse effects in rodent, canine, and porcine models. Second, the two published Phase I human safety trials tested markedly different dose ranges—Ruff and colleagues (2010) used absolute doses of 42 to 1,260 mg intravenously, while Wang and colleagues (2021) used weight-based doses of 0.05 to 25.0 μg/kg—reflecting different clinical development strategies rather than contradictory findings. Third, and critically, virtually all of this data applies to full-length thymosin beta-4, not to the TB-500 fragment. No published study has established a dosing protocol specifically for the 7-amino-acid TB-500 in humans, and extrapolating doses between the two molecules involves assumptions about relative bioactivity and pharmacokinetics that have not been validated.
| Study | Molecule | Route | Dose | Schedule | Subjects / Species | Key Result | Citation |
|---|---|---|---|---|---|---|---|
| Phase I safety (US, RegeneRx) | Tβ4 | IV | 42–1,260 mg (single dose, 4 cohorts) | Single dose, then daily ×14 days at same level | 40 healthy volunteers | No dose-limiting toxicities or SAEs; dose-proportional PK | Ruff et al. (2010) Ann. N.Y. Acad. Sci. |
| Phase I safety (China, NL005) | Tβ4 | IV | 0.05–25.0 μg/kg (single dose, 7 cohorts) | Single dose; then daily ×10 days (3 multi-dose cohorts) | 54 healthy volunteers (single); 30 (multiple) | No serious AEs; no accumulation; well tolerated | Wang et al. (2021) J. Cell. Mol. Med. |
| Cardiac pilot | Tβ4 | IV | Not publicly detailed | Post-MI administration | Post-STEMI patients | First human cardiac study; potential clinical benefits reported | Zhu et al. (2016) Cytotherapy |
| Dry eye Phase II | Tβ4 | Topical | 0.1% solution (RGN-259 eye drops) | Twice daily ×28 days | 72 subjects (1:1 randomized) | Significant corneal staining improvement; no AEs | Sosne et al. (2015) Clin. Ophthalmol. |
| NK Phase III (SEER-1) | Tβ4 | Topical | 0.1% solution (RGN-259 eye drops) | Five times daily ×4 weeks | NK patients (rare disease) | 60% achieved complete corneal healing | Kleinman et al. (2023) Int. J. Mol. Sci. |
| Venous ulcer trial | Tβ4 | Topical | 0.03% gel | Applied to wound ×84 days | Venous stasis ulcer patients | Safety and tolerability confirmed | Guarnera et al. (2010) Ann. N.Y. Acad. Sci. |
| Coronary ligation (landmark) | Tβ4 | IP | Not specified (pre-treatment protocol) | Pre-injury and post-injury | Mouse | Akt activation, reduced cell death, improved cardiac function | Bock-Marquette et al. (2004) Nature |
| Chronic MI (short and long term) | Tβ4 | IP | 5.37–5.4 mg/kg | Short-term: days 1–3; Long-term: day 1–3 then every 3rd day | Rat | Both regimens improved cardiac function | Bao et al. (2013) Front. Pharmacol. |
| Chronic myocardial ischemia | Tβ4 | IV | 6 mg/kg | Two doses: pre-ischemia + 6 hrs post | Pig | Elevated serum Tβ4 confirmed; large-animal safety data | Stark et al. (2016) Front. Pharmacol. |
| Embolic stroke (dose-response) | Tβ4 | IP | 2, 12, 18 mg/kg | 24 hrs post-MCAo, then every 3 days ×4 doses | Rat | Optimal efficacy at 6–12 mg/kg; ceiling effect at 18 mg/kg | Morris et al. (2014) Ann. N.Y. Acad. Sci. |
| TBI (6 hr post-injury) | Tβ4 | IP | 6 and 30 mg/kg | 6 hrs post-injury, then at 24 and 48 hrs | Rat | Both doses reduced lesion volume; higher dose showed better outcomes | Xiong et al. (2012) J. Neurosurg. |
| TBI (delayed treatment) | Tβ4 | IP | 6 mg/kg | Day 1 post-injury, then every 3 days ×4 doses | Rat | Improved functional recovery, enhanced neurogenesis | Xiong et al. (2011) J. Neurosurg. |
| Skin wound healing | Tβ4 | IP / Topical | 5 μg topical; 6 mg/kg IP | Applied to wound / post-wounding | Rat | Reepithelialization increased 42% (day 4), 61% (day 7) vs. controls | Malinda et al. (1999) J. Invest. Derm. |
| Corneal injury (alkali burn) | Tβ4 | Topical | 0.1% solution | Multiple daily applications | Rat | Promoted healing, decreased pro-inflammatory cytokines | Sosne et al. (2002) Exp. Eye Res. |
| Dystrophin-deficient (mdx) model | Tβ4 | IP | 6 mg/kg | Chronic administration | Mouse | Improvements in skeletal and cardiac muscle function | Spurney et al. (2010) PLoS One |
The following table describes dosing protocols that are commonly discussed in online forums, podcasts, practitioner websites, and social media groups where individuals report on their own independent experimentation with TB-500. This information is compiled from publicly available discussions and is presented here as a factual account of what is circulating in these communities—not as a recommendation, endorsement, or validation of any protocol.
Disclaimer: The protocols described below are drawn from anecdotal self-reports in uncontrolled settings. They have not been validated in clinical trials. The individuals reporting these experiences are not operating under IRB oversight, and their reports are subject to placebo effects, confirmation bias, variation in product quality and purity, and the absence of objective outcome measures. Peptidings does not advocate for, recommend, or endorse any self-experimentation protocol. This information is provided solely because it exists in the public discourse, and we believe readers are better served by seeing it presented alongside its limitations than by encountering it without context elsewhere.
| Parameter | Commonly Reported | Range Observed | Route | Notes |
|---|---|---|---|---|
| Loading dose | 2.0–2.5 mg per injection, twice weekly | 4–10 mg per week total | Subcutaneous (most common) or intramuscular | Typical loading phase reported as 4–6 weeks; some community guidelines suggest ~1 mg per 25 lbs of body weight per week as a rough scaling rule |
| Maintenance dose | 2.0 mg once weekly to once every two weeks | 2–4 mg per week | Subcutaneous | Follows loading phase; some individuals report monthly injections for long-term maintenance; duration varies widely from 2–6 additional weeks to ongoing |
| Injection site | Abdominal subcutaneous fat; some report near injury site | Abdomen, thigh, near affected area | Subcutaneous preferred; intramuscular near injury also reported | Unlike BPC-157, TB-500 is generally described as having systemic rather than localized effects; most community sources suggest injection site is less critical than with BPC-157 |
| Typical cycle length | 6–8 weeks total (loading + maintenance) | 4–12 weeks | N/A | Chronic or post-surgical recovery protocols often reported as longer (up to 12 weeks); some individuals report ongoing low-dose monthly maintenance indefinitely |
| Reconstitution | Bacteriostatic water added to lyophilized vial (typically 2 mL per 5 mg vial) | 0.4–3 mL per vial | N/A | TB-500 typically sold in 2 mg or 5 mg lyophilized vials; less bacteriostatic water yields a more concentrated solution and smaller injection volume; gentle swirling (not shaking) recommended |
| Combination protocols (stacking) | TB-500 + BPC-157 (Wolverine Protocol) | TB-500 2–5 mg 2x/week + BPC-157 250–500 μg/day; also GLOW and KLOW multi-peptide protocols | Separate injections (not mixed in same syringe) | Combining TB-500 with BPC-157 is the most widely discussed combination; no published research validates any combination protocol; interaction profiles are entirely uncharacterized |
| Commonly reported side effects | Head rush, mild lethargy, localized cramping near injection site | N/A | N/A | Some forum users report muscle cramping in areas adjacent to injection sites; this is anecdotal and unverified; the absence of reported side effects in online forums does not constitute evidence of safety |
Sources: These protocols are drawn from Reddit communities (particularly r/Peptides), biohacking podcasts, longevity forums, practitioner-authored blog posts, and social media discussions. The quality and reliability of these sources varies enormously. Some individuals reporting their experiences are physicians or researchers; many are not. There is no way to independently verify the accuracy of self-reported outcomes.
Critical distinction: Published research—even the small pilot studies listed in the dosing table above—includes baseline blood work, vital sign monitoring, and systematic screening for adverse effects. Self-experimentation typically does not. The absence of reported side effects in online forums does not constitute evidence of safety; it reflects the absence of systematic monitoring.
A note on dose scaling: The standard animal dose of approximately 6 mg/kg, if scaled to a 70 kg human using simple body weight conversion, would correspond to roughly 420 mg—vastly higher than the 2–5 mg doses typically discussed in self-experimentation communities. Dose scaling between species is not a straightforward matter of body weight—factors including metabolic rate, body surface area, and bioavailability all affect how a dose translates across species. The doses circulating in self-experimentation communities appear to have been derived from a combination of rough allometric scaling, practitioner experimentation, and community consensus rather than from formal pharmacokinetic studies. It is also worth noting that TB-500 is a 7-amino-acid fragment, not the full 43-amino-acid Tβ4 molecule used in published studies, which adds an additional layer of uncertainty to any dose extrapolation.
Is TB-500 FDA approved?
No. Neither TB-500 nor full-length thymosin beta-4 is currently approved by the U.S. Food and Drug Administration for general medical use. Full-length Tβ4 is being developed as a pharmaceutical candidate by RegeneRx Biopharmaceuticals, with clinical trials in ophthalmic and cardiac applications, but regulatory approval has not been granted.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4, which is a 43-amino-acid naturally occurring protein. They share the actin-binding motif but differ in size, domain composition, and potentially in their range of biological activity. Most published research was conducted on the full-length protein.
Is TB-500 banned in sports?
Yes. TB-500, thymosin beta-4, and all related derivatives are prohibited by the World Anti-Doping Agency under Section S2 of the Prohibited List, at all times (in-competition and out-of-competition). This prohibition has been in effect since 2018 and also applies to competitive horse racing and U.S. military personnel subject to WADA-aligned testing.
Does TB-500 cause cancer?
The relationship between Tβ4 and cancer is complex and unresolved. Tβ4 is overexpressed in several tumor types, and its pro-migratory, angiogenic, and anti-apoptotic properties theoretically could promote tumor growth and metastasis. However, some studies have found anti-tumor effects in specific cancer contexts. No causal link between exogenous TB-500 administration and cancer development has been established, but the theoretical concern is legitimate and long-term data is lacking.
Where can I find peer-reviewed research on TB-500?
Searching PubMed for “thymosin beta-4” will return the most comprehensive results, as the majority of published research uses this term rather than “TB-500.” Useful search strategies include combining thymosin beta-4 with specific tissue or condition terms — for example, “thymosin beta-4 cardiac,” “thymosin beta-4 corneal,” or “thymosin beta-4 neuroprotection.”
Researchers studying TB-500 frequently encounter related peptides that operate in overlapping or complementary biological territories. Understanding where these compounds converge and diverge provides essential context for evaluating each one individually.
BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective compound found in human gastric juice, and it is the compound most frequently discussed alongside TB-500. Where TB-500 operates primarily through actin sequestration and cell migration, BPC-157’s proposed mechanism centers on VEGF-mediated angiogenesis and fibroblast activation. The two peptides thus address different bottlenecks in the tissue repair process: BPC-157 promotes blood vessel formation to deliver oxygen and nutrients to damaged areas, while TB-500 promotes the migration of repair cells into those areas. This complementary profile is the rationale behind the “Wolverine Protocol” discussed in self-experimentation communities, though no published research validates this combination. BPC-157 has a deeper literature in tendon and ligament repair and gastrointestinal protection, while TB-500’s parent molecule has more advanced clinical trial data in cardiac and ophthalmic applications. For a comprehensive overview, see our dedicated BPC-157 article.
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper-binding tripeptide whose mechanism is fundamentally different from TB-500’s. Rather than acting through cytoskeletal regulation or growth factor signaling, GHK-Cu delivers copper ions to tissues where copper serves as a cofactor for enzymes involved in collagen synthesis, elastin production, and extracellular matrix remodeling. Its research profile skews heavily toward skin biology—wound healing, scar remodeling, and age-related skin changes. GHK-Cu is widely commercially available in topical cosmetic formulations, giving it a far larger consumer footprint than TB-500 despite a narrower therapeutic research profile. GHK-Cu appears in the “GLOW” and “KLOW” multi-peptide protocols discussed in self-experimentation communities, where it adds a collagen-remodeling component to the BPC-157/TB-500 base.
Thymosin Alpha-1
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland, and it is the most clinically advanced compound in this family by a significant margin. Unlike TB-500, Thymosin Alpha-1 is an approved prescription medication in over 35 countries, marketed under the trade name Zadaxin for hepatitis B and C treatment and as an immune adjuvant in certain cancer protocols. Its mechanism—enhancing dendritic cell and T-lymphocyte function—is fundamentally different from TB-500’s cytoskeletal regulation. Its regulatory approval history provides a valuable reference point for understanding what the pathway from preclinical research to approved therapeutic actually looks like, and how far both TB-500 and BPC-157 still have to travel along that path.
Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline)
Ac-SDKP is another peptide fragment derived from thymosin beta-4, but from a different region (amino acids 1–4) than TB-500 (amino acids 17–23). It is released from Tβ4 by the enzyme prolyl oligopeptidase and has been studied primarily for anti-fibrotic and anti-inflammatory effects, particularly in cardiovascular and renal research. Ac-SDKP is naturally regulated by ACE (angiotensin-converting enzyme), which is why ACE inhibitors increase its levels. It is important not to conflate Ac-SDKP research with TB-500 research, as the two fragments derive from different regions of the parent molecule and have distinct biological activities.
Side-by-Side Comparison
The five compounds discussed in this section—TB-500, BPC-157, GHK-Cu, Thymosin Alpha-1, and Ac-SDKP—are the peptides most frequently encountered by researchers and informed readers exploring the tissue-repair and regenerative peptide landscape. Each operates through a fundamentally different mechanism, targets different tissues, and sits at a different stage of clinical development. Understanding where these compounds converge and diverge is essential for evaluating any one of them honestly, and for recognizing when marketing language conflates peptides that have little in common beyond the word “peptide.”
The comparison table that follows summarizes these differences across several dimensions that matter for evaluating the research: molecular characteristics, proposed mechanism, primary tissue targets, volume and maturity of the published literature, clinical trial status, regulatory and anti-doping classification, and the specific safety considerations unique to each compound. Brief profiles of each peptide precede the table so that readers arriving at this article first—rather than through our BPC-157 or other pillar articles—have sufficient context to interpret the comparison.
TB-500 is the subject of this article: a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the 43-amino-acid protein thymosin beta-4. Its primary mechanism is actin sequestration and the promotion of cell migration into damaged tissue. The parent molecule Tβ4 has reached Phase III clinical trials for corneal wound healing and has Phase I human safety data for systemic administration. TB-500 itself—the fragment—has not been studied in any published human clinical trial. It is prohibited by WADA at all times and is not FDA-approved. The cancer risk associated with Tβ4’s overexpression in multiple tumor types is the most significant safety consideration unique to this compound.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. Where TB-500 works through cytoskeletal regulation and cell migration, BPC-157’s proposed mechanism centers on VEGF-mediated angiogenesis (the formation of new blood vessels) and fibroblast activation. This makes it mechanistically complementary to TB-500 rather than redundant—which is the biological rationale behind the “Wolverine Protocol” combination discussed in self-experimentation communities. BPC-157 has over three decades of preclinical research, primarily from the University of Zagreb, and three small published human pilot studies covering intraarticular knee pain, interstitial cystitis, and intravenous safety. Its research profile is deepest in tendon and ligament repair and gastrointestinal protection. It is not FDA-approved and was placed on the FDA’s Category 2 bulk drug substance list, restricting compounding pharmacy access. For a comprehensive overview, see our dedicated BPC-157 article.
GHK-Cu (glycine-histidine-lysine copper) is a naturally occurring copper-binding tripeptide first identified in human plasma in the 1970s. Its mechanism is fundamentally different from both TB-500 and BPC-157: rather than acting through growth factor signaling or cytoskeletal regulation, GHK-Cu delivers copper ions to tissues where copper serves as an enzymatic cofactor for collagen synthesis, elastin production, and extracellular matrix remodeling. The research profile skews heavily toward skin biology—wound healing, scar remodeling, and age-related structural changes—and the compound is widely commercially available in topical cosmetic formulations without prescription. This gives it a far larger consumer footprint than TB-500 despite a much narrower therapeutic research profile. Systemic administration of GHK-Cu has been studied far less extensively than topical application. GHK-Cu is not prohibited by WADA and is not subject to the same regulatory restrictions as TB-500 or BPC-157.
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland, and it is the most clinically advanced compound in this group by a significant margin. Unlike every other peptide in this comparison, Thymosin Alpha-1 is an approved prescription medication in over 35 countries, marketed under the trade name Zadaxin for the treatment of hepatitis B and C and as an immune adjuvant in certain cancer protocols. Its mechanism—enhancing dendritic cell and T-lymphocyte maturation and function—is fundamentally different from the tissue-repair mechanisms of TB-500, BPC-157, and GHK-Cu. Its inclusion in this comparison reflects the broader interest in “peptide therapy” rather than a direct mechanistic overlap with TB-500. However, the immune system plays an integral role in orchestrating tissue repair, so understanding Thymosin Alpha-1’s pathway adds context. More importantly, its regulatory approval history provides a concrete reference point for understanding what the journey from preclinical research to approved therapeutic actually requires—and how far the other compounds in this table still have to travel.
Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is included specifically because it derives from the same parent molecule as TB-500—thymosin beta-4—but from a different functional region (amino acids 1–4 rather than 17–23). It is released from Tβ4 by the enzyme prolyl oligopeptidase and has been studied primarily for anti-fibrotic effects in cardiovascular and renal research. Ac-SDKP is naturally regulated by angiotensin-converting enzyme (ACE), which is why ACE inhibitors increase its circulating levels—a relationship that has generated significant research interest in cardiology. Despite sharing a parent molecule with TB-500, Ac-SDKP has a distinct biological identity: its primary activity is anti-fibrotic rather than pro-migratory, and conflating the two fragments is a common error in non-specialist sources. It is not commercially available as a research peptide in the way TB-500 is, and it occupies a different position in the research pipeline.
| Dimension | BPC-157 | TB-500 / Tβ4 | GHK-Cu | Thymosin Alpha-1 | KPV | LL-37 | VIP |
|---|---|---|---|---|---|---|---|
| Type | Synthetic 15-aa pentadecapeptide from gastric juice | Synthetic 7-aa fragment; parent is 43-aa endogenous protein | Natural copper-binding tripeptide (3 aa + Cu²⁺) | 28-aa synthetic peptide; identical to endogenous thymic peptide | Tripeptide (3 aa) derived from α-MSH | 37-aa human cathelicidin antimicrobial peptide | 28-aa endogenous neuropeptide; neuroimmune regulator |
| Primary Mechanism | VEGF angiogenesis; fibroblast activation; collagen synthesis; NO system modulation; GABAergic/dopaminergic activity | Actin sequestration; cell migration; Akt/ILK survival signaling; Notch-mediated angiogenesis | Copper delivery; enzymatic activation (lysyl oxidase, SOD); gene expression modulation (~4,000 genes); ECM remodeling | Immune modulation; T-cell maturation; dendritic cell/NK cell activation; TLR signaling; bidirectional cytokine balance | Anti-inflammatory; NF-κB pathway modulation; PepT1 transporter-mediated uptake; cytokine suppression (TNF-α, IL-6) | Membrane disruption of bacterial/fungal pathogens; anti-biofilm activity; EGFR transactivation; keratinocyte migration; angiogenesis promotion | Potent anti-inflammatory neuropeptide; VPAC1/VPAC2 receptor activation; cAMP/PKA signaling; immune tolerance promotion; vasodilation; circadian rhythm regulation |
| Primary Tissue Targets | Tendons, ligaments, GI mucosa, bone, muscle, peripheral nerves | Cardiac, corneal, dermal, neurological, musculoskeletal | Skin (primary); wounds; ECM broadly; emerging systemic research | Immune system: hepatitis, cancer adjunct, sepsis, vaccine enhancement | GI tract (IBD, colitis); skin (inflammatory conditions); mucosal surfaces | Infected wounds; mucosal surfaces; skin; biofilm-forming infections; cornea | Lungs (pulmonary vasodilation); GI tract; CNS (circadian, neuroprotection); immune system (autoimmune/inflammatory conditions) |
| Human Clinical Evidence | Three small pilot studies (knee OA, interstitial cystitis, IV safety); no large RCTs | Phase I safety (IV); cardiac pilot; Phase II/III ophthalmic trials — all full-length Tβ4, not TB-500 fragment | Multiple topical cosmetic trials (wrinkles, collagen, photoaging); limited wound-healing data; no systemic/injectable human trials | Approved drug in 35+ countries (Zadaxin); 3,000+ patients in clinical trials; Phase III sepsis trial (TESTS, 1,106 patients) | No published human clinical trials | LL-37 derivatives in early clinical trials for wound infection; LL-37 itself primarily studied in human tissue/wound biopsy studies; no Phase III RCTs for the peptide itself | Aviptadil (synthetic VIP) granted FDA Fast Track for COVID-19 respiratory failure; limited human data for other indications; compounded nasal spray used clinically for CIRS |
| WADA Status | Prohibited (S0: Non-Approved Substances) | Prohibited at all times (S2: Growth Factors, since 2018) | Not prohibited | Not prohibited; approved prescription medication | Not prohibited | Not specifically listed; athletes should verify | Not specifically listed; athletes should verify |
| FDA / Regulatory Status | Category 2 (restricted from 503A/503B compounding); not approved for any indication | Not approved; research chemical; full-length Tβ4 (not TB-500) in FDA ophthalmic pipeline via RegeneRx | Category 1 for 503A compounding (non-injectable routes only); injectable restricted; topical cosmetic products freely available OTC | Orphan drug designation for 4 indications; Category 2 restricts compounding; not approved for general US use; approved in 35+ countries as Zadaxin | Not approved; research chemical; no FDA category designation | Not approved for therapeutic use; derivatives (e.g., omiganan) in clinical development; research chemical | FDA reviewing status as bulk compound; compounded nasal spray available by prescription; aviptadil (synthetic VIP) has FDA Fast Track designation |
| Unique Safety Concern | Research concentrated in single group (Sikiric et al.); limited independent replication; long-term data absent; Category 2 FDA restriction | Tβ4 overexpressed in multiple tumor types; theoretical cancer promotion risk applies to parent molecule; fragment-specific safety unknown | Copper accumulation risk with chronic systemic use; very short plasma half-life (~30 min) limits injectable bioavailability; injectable safety uncharacterized in humans | Immune modulation inherently unpredictable in autoimmune conditions; contraindicated with deliberate immunosuppression (organ transplant) | Very limited safety data; smallest published research base in Cluster B; tripeptide structure suggests low toxicity but this is inference, not evidence | Dose-dependent cytotoxicity at high concentrations; can be pro-inflammatory in excess (psoriasis, rosacea associated with overexpression); narrow therapeutic window | Very short half-life (~2 minutes IV); limited controlled human safety data for most proposed indications; potential immunosuppressive effects at high doses |
| Evidence Tier | Pilot/Limited Human Data | It’s Complicated — clinical trial data applies to full-length Tβ4; no published trials for the TB-500 fragment | It’s Complicated — decades of topical human data; systemic injectable evidence is preclinical only | Approved Drug (Zadaxin, 35+ countries; not FDA-approved in US) | Preclinical Only | Preclinical Only (peptide itself); derivatives in early clinical trials | Pilot/Limited Human Data (aviptadil Fast Track; compounded clinical use for CIRS; limited controlled trial data) |
Several patterns emerge from this side-by-side view that are worth noting. First, these peptides arrive at superficially similar outcomes—tissue repair, healing, recovery—through fundamentally different biological pathways. TB-500 regulates the cytoskeleton. BPC-157 builds blood vessels. GHK-Cu remodels the extracellular matrix. Thymosin Alpha-1 modulates immunity. Ac-SDKP inhibits fibrosis. The fact that different mechanisms can produce overlapping therapeutic outcomes underscores how complex tissue repair actually is. Second, the evidence profiles diverge dramatically: Thymosin Alpha-1 is an approved drug in dozens of countries, TB-500’s parent molecule has Phase III data, BPC-157 has three small pilot studies, GHK-Cu has primarily cosmetic data, and Ac-SDKP is studied as an endogenous biomarker rather than an exogenous therapeutic. Third, the regulatory and anti-doping landscape varies enormously—from GHK-Cu (freely available in cosmetics) to TB-500 (explicitly prohibited by WADA at all times). Readers evaluating any of these compounds should understand where it sits on each of these dimensions before drawing conclusions about its suitability for any purpose.
For deeper exploration of any of these related peptides, see our dedicated articles on BPC-157, GHK-Cu, and Thymosin Alpha-1, as well as our peptide glossary for definitions of technical terms used throughout this section.
Combination Protocols and the “Stacking” Question
In self-experimentation communities, TB-500 and BPC-157 are frequently discussed as a combination—sometimes called the “Wolverine Protocol”—on the theory that their complementary mechanisms (TB-500 promoting cell migration into injured tissue while BPC-157 drives blood vessel formation and fibroblast activity) might produce synergistic effects. It is important to note that no published research validates this combination protocol. The Lee and Padgett 2021 knee study did use BPC-157 alongside Tβ4 in four patients, but the study was not designed to evaluate synergy between the two peptides, and the combined group was too small to draw meaningful conclusions.
Beyond the two-peptide TB-500/BPC-157 combination, online experimentation communities and some practitioner clinics have developed named multi-peptide protocols that incorporate the compounds discussed in this section. The most widely circulated are the “Wolverine” protocol (TB-500 + BPC-157, targeting musculoskeletal repair), the “GLOW” protocol (TB-500 + BPC-157 + GHK-Cu, adding a collagen and skin-remodeling component), and the “KLOW” protocol (TB-500 + BPC-157 + GHK-Cu + KPV, a four-peptide stack that adds the anti-inflammatory tripeptide KPV, derived from alpha-melanocyte-stimulating hormone, to address inflammation more directly).
The rationale offered in these communities is that each successive protocol layers an additional biological pathway—cell migration, then angiogenesis, then extracellular matrix remodeling, then cytokine modulation—to create what proponents describe as more comprehensive regenerative support. These names now appear on research-chemical supplier websites, in practitioner-authored blogs, and in dedicated forums, and they have become a shared vocabulary in the self-experimentation space.
It bears repeating that none of these combination protocols have been validated in published research. No study has examined whether these specific peptides produce additive or synergistic effects when administered together, and the interaction profiles—including whether one peptide’s activity might interfere with another’s—are entirely uncharacterized. The named protocols represent community-generated hypotheses, not evidence-based regimens, and readers should evaluate them accordingly.
TB-500 is a synthetic heptapeptide derived from the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein present in nearly all mammalian cells. The parent molecule Tβ4 has been the subject of decades of research spanning cell biology, cardiac medicine, ophthalmology, neuroscience, and wound healing, with a research base that is broader and more clinically advanced than that of most research peptides.
The proposed mechanisms of action—actin sequestration, cell migration promotion, angiogenesis, anti-apoptotic signaling, and anti-inflammatory activity—are well characterized at the preclinical level and have been explored in multiple human clinical trials using the full-length Tβ4 molecule. Key research areas include cardiac repair (Phase I safety data, pilot cardiac study), corneal wound healing (Phase II and III trials), dermal wound healing, and neuroprotection after traumatic brain injury.
However, several critical caveats must be acknowledged. First, the human clinical data exists for full-length thymosin beta-4, not for the TB-500 fragment; extrapolating the parent molecule’s safety and efficacy profile to the fragment requires assumptions that have not been validated. Second, the cancer concern—rooted in Tβ4’s overexpression in multiple tumor types—remains unresolved and represents a legitimate safety consideration that is distinct from the risk profiles of most other research peptides. Third, TB-500 is prohibited by WADA and is not FDA-approved for any use.
For researchers, the most meaningful developments to watch are the continued progression of the RGN-259 ophthalmic program through FDA regulatory review, the advancement of RGN-352 into cardiac Phase II trials, and any published research specifically examining the TB-500 fragment in controlled human studies. For anyone outside of regulated clinical trials, the gap between “promising preclinical and early clinical evidence for the parent molecule” and “validated safety and efficacy for the commercially available fragment” remains significant.
The broader lesson of the TB-500 story is that the research pipeline matters. A compound can have genuine scientific promise—and Tβ4 does—while still being years away from the kind of evidence base that would justify confident claims about human safety and efficacy. Understanding where a compound sits on that pipeline, and being honest about the gaps, is the foundation of responsible peptide science.
The following citations represent a cross-section of the peer-reviewed literature on thymosin beta-4 and TB-500, organized into two groups. The first includes foundational studies that established the peptide’s core research profile across cardiac repair, wound healing, neuroprotection, and actin biology. The second highlights recent publications available as free full text through PubMed Central, offering readers immediate access to the current state of the field.
Together, these references illustrate both the depth of the existing evidence base and the breadth of independent research groups contributing to the literature—a notable contrast with some other research peptides where publications are concentrated in a single laboratory. This list is not exhaustive; readers are encouraged to search PubMed for “thymosin beta-4” and “TB-500” in combination with specific tissues or mechanisms of interest to explore the broader literature.
Foundational Studies
- Low, Thomas L. K., Suk-Ki Hu, and Allan L. Goldstein. 1981. “Complete Amino Acid Sequence of Bovine Thymosin Beta 4: A Thymic Hormone That Induces Terminal Deoxynucleotidyl Transferase Activity in Thymocyte Populations.” Proceedings of the National Academy of Sciences 78 (2): 1162–66. doi:10.1073/pnas.78.2.1162.
- Malinda, Kim M., Gayle S. Sidhu, Harshani Banaudha, Hua Zhu, Deepak Srivastava, and Hynda K. Kleinman. 1999. “Thymosin β4 Accelerates Wound Healing.” Journal of Investigative Dermatology 113 (3): 364–68. doi:10.1046/j.1523-1747.1999.00708.x.
- Bock-Marquette, Ildiko, Anand Saxena, Michael D. White, J. Michael DiMaio, and Deepak Srivastava. 2004. “Thymosin β4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration, Survival and Cardiac Repair.” Nature 432 (7016): 466–72. doi:10.1038/nature03000.
- Sosne, Gabriel, Elizabeth A. Siddiqi, and May Kurpakus-Wheater. 2004. “Thymosin-β4 Inhibits Corneal Epithelial Cell Apoptosis after Ethanol Exposure In Vitro.” Investigative Ophthalmology & Visual Science 45 (4): 1095–1100. doi:10.1167/iovs.03-1002.
- Ruff, Darrell, David Crockford, Gail Girardi, and Yue Zhang. 2010. “A Randomized, Placebo-Controlled, Single and Multiple Dose Study of Intravenous Thymosin β4 in Healthy Volunteers.” Annals of the New York Academy of Sciences 1194 (1): 223–29. doi:10.1111/j.1749-6632.2010.05474.x.
- Xiong, Ye, Asim Mahmood, Yanlu Meng, Yuling Zhang, Zheng Gang Zhang, Daniel C. Morris, and Michael Chopp. 2011. “Treatment of Traumatic Brain Injury with Thymosin β₄ in Rats.” Journal of Neurosurgery 114 (1): 102–15. doi:10.3171/2010.4.JNS10118.
- Goldstein, Allan L., Ewald Hannappel, Gabriel Sosne, and Hynda K. Kleinman. 2012. “Thymosin β4: A Multi-Functional Regenerative Peptide. Basic Properties and Clinical Applications.” Expert Opinion on Biological Therapy 12 (1): 37–51. doi:10.1517/14712598.2012.634793.
- Bao, Weihua, Victoria L. Ballard, Steven Needle, Binh Hoang, Steven C. Lenhard, Jason R. Tunstead, Brian M. Jucker, Robert N. Willette, and G. Thomas Pipes. 2013. “Cardioprotection by Systemic Dosing of Thymosin Beta Four Following Ischemic Myocardial Injury.” Frontiers in Pharmacology 4: 149. doi:10.3389/fphar.2013.00149.
- Xiong, Ye, Yanlu Zhang, Asim Mahmood, Yanlu Meng, Zheng Gang Zhang, Daniel C. Morris, and Michael Chopp. 2012. “Neuroprotective and Neurorestorative Effects of Thymosin β4 Treatment Initiated 6 Hours after Traumatic Brain Injury in Rats.” Journal of Neurosurgery 116 (5): 1081–92. doi:10.3171/2012.1.JNS111729.
- Zhu, Junhui, Junhao Song, Liang Yu, Huimin Zheng, Binbin Zhou, Shaohua Weng, and Guosheng Fu. 2016. “Safety and Efficacy of Autologous Thymosin β4 Pre-Treated Endothelial Progenitor Cell Transplantation in Patients with Acute ST Segment Elevation Myocardial Infarction.” Cytotherapy 18 (8): 1037–42. doi:10.1016/j.jcyt.2016.05.006.
Recent Literature (Free Full Text)
The following articles were published within the past three years and are available as open-access full text through PubMed Central (PMC) or publisher open-access programs. The Wang et al. Phase I trial provides the most current human pharmacokinetic and safety data for recombinant Tβ4. The Kleinman et al. Phase III ophthalmic trial represents the most advanced clinical evidence for any Tβ4-based therapeutic. The Stewart et al. study extends neuroprotection research into blood-brain barrier mechanisms. The Maar et al. study represents the newest cardiac remodeling data. These publications, taken together, offer the most current and accessible snapshot of Tβ4 science as of early 2026.
- Wang, Xinghe, Long Liu, Lu Qi, Chunpu Lei, Pu Li, Yu Wang, Chen Liu, Haihong Bai, Chengquan Han, Yinjian Sun, and Jincan Liu. 2021. “A First-in-Human, Randomized, Double-Blind, Single- and Multiple-Dose, Phase I Study of Recombinant Human Thymosin β4 in Healthy Chinese Volunteers.” Journal of Cellular and Molecular Medicine 25 (17): 8222–28. doi:10.1111/jcmm.16693. Free full text: PMC8419187.
- Kleinman, Hynda K., Gabriel Sosne, David Crockford, and Allan L. Goldstein. 2023. “0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.” International Journal of Molecular Sciences 24 (1): 554. doi:10.3390/ijms24010554. Free full text: PMC9820434.
- Maar, Klaudia, Jon E. Thatcher, Evgeny Karpov, Szilard Rendeki, Ferenc Gallyas Jr., and Ildiko Bock-Marquette. 2025. “Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals.” International Journal of Molecular Sciences 26 (5): 2153. doi:10.3390/ijms26052153. Free full text: available via MDPI.
- Stewart, William G., Christina D. Hejl, Rakeshwar S. Guleria, and Sudhiranjan Gupta. 2025. “Thymosin β4 Stabilizes Hypoxia Induced Brain Microvascular Endothelial Cell Dysfunction through S1PR1 Dependent Mechanisms.” Scientific Reports 15: 28435. doi:10.1038/s41598-025-28435-2. Free full text: available via Nature.
- Ho, Emmie N. M., Wai K. Kwok, Maureen Y. K. Lau, Amy S. Y. Wong, Terence S. M. Wan, Kenneth K. H. Lam, Philip J. Schiff, and Brian D. Stewart. 2012. “Doping Control Analysis of TB-500, a Synthetic Version of an Active Region of Thymosin β4, in Equine Urine and Plasma by Liquid Chromatography–Mass Spectrometry.” Journal of Chromatography A 1265: 57–69. doi:10.1016/j.chroma.2012.09.043. (Included as the primary characterization of TB-500 as a distinct molecule from full-length Tβ4.)
For those interested in exploring the primary literature, searching PubMed for “thymosin beta-4” will return the most comprehensive results. The peptide has been studied across numerous research groups and institutions worldwide, with a particularly strong publication history in cardiac, ophthalmic, and neurological research. Useful search strategies include combining “thymosin beta-4” with specific areas of interest—for example, “thymosin beta-4 cardiac repair,” “thymosin beta-4 corneal healing,” or “thymosin beta-4 neuroprotection.”
Key foundational references include Low, Hu, and Goldstein (1981) for the original amino acid sequence characterization; Bock-Marquette, Saxena, White, DiMaio, and Srivastava (2004) for the landmark cardiac repair study; Goldstein, Hannappel, Sosne, and Kleinman (2012) for a comprehensive review of basic properties and clinical applications; Xiong, Mahmood, and Chopp (2012) for the neuroprotection research; and Wang and colleagues (2021) for the Phase I human pharmacokinetic data.
Peptidings provides educational information about peptide science and emerging research developments. The content on this site is not intended to diagnose, treat, cure, or prevent any disease and should not be interpreted as medical advice. Peptides discussed on this site are investigational compounds typically studied in laboratory environments. Always consult a qualified health-care professional before making decisions based on the information presented here.